STIM vs ABSI

For growth investors, Neuronetics, Inc.

(STIM) is the stronger pick with 99. 2% revenue growth year-over-year, versus -38. 2% for Absci Corporation (ABSI). Analysts rate Neuronetics, Inc. (STIM) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Absci Corporation (ABSI) delivered a total return of -72.

4%, compared to -85. 5% for Neuronetics, Inc. (STIM). Over 10 years, the gap is even starker: ABSI returned -72. 4% versus STIM's -93. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Neuronetics, Inc.

(STIM) is the lower-risk stock at 1. 90β versus Absci Corporation's 2. 82β — meaning ABSI is approximately 48% more volatile than STIM relative to the S&P 500. On balance sheet safety, Absci Corporation (ABSI) carries a lower debt/equity ratio of 3% versus 3% for Neuronetics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Neuronetics, Inc.

(STIM) is pulling ahead at 99. 2% versus -38. 2% for Absci Corporation (ABSI). On earnings-per-share growth, the picture is similar: Neuronetics, Inc. grew EPS 57. 2% year-over-year, compared to 10. 6% for Absci Corporation. Over a 3-year CAGR, STIM leads at 31. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Neuronetics, Inc.

(STIM) is the more profitable company, earning -26. 1% net margin versus -41. 1% for Absci Corporation — meaning it keeps -26. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: STIM leads at -21. 1% versus -44. 5% for ABSI. At the gross margin level — before operating expenses — STIM leads at 48. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Neuronetics, Inc.

(STIM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Absci Corporation (ABSI) carries a higher beta of 2. 82 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (STIM: -93. 1%, ABSI: -72. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: STIM is a small-cap high-growth stock; ABSI is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.